349 results match your criteria Controversies in Prostate Cancer


Selective androgen receptor modulators: the future of androgen therapy?

Transl Androl Urol 2020 Mar;9(Suppl 2):S135-S148

Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.

Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional androgen therapy. SARMs have few side effects and excellent oral and transdermal bioavailability and may, therefore, represent viable alternatives to current androgen therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2019.11.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108998PMC

Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol.

Methods Protoc 2020 Mar 28;3(2). Epub 2020 Mar 28.

UCL Division of Surgery and Interventional Science, University College London, London W1W 7TY, UK.

Background: The introduction of multiparametric magnetic resonance imaging (mpMRI) has improved the diagnosis of suspected prostate cancer, accurately risk-stratifying men before a biopsy. However, pre-biopsy mpMRI represents a significant deviation from the traditional approach of prostate specific antigen testing with subsequent systematic transrectal ultrasound-guided prostate biopsy and we have not yet explored the views of men who experience this new pathway. The purpose of the PACT study (PAtient views and aCceptance of mulTiparametric MRI) is to explore men's perceptions of mpMRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/mps3020026DOI Listing

The role of ErbB4 in cancer.

Cell Oncol (Dordr) 2020 Jun 26;43(3):335-352. Epub 2020 Mar 26.

Laboratory of Physiopharmacology, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.

Background: The epidermal growth factor receptor family consists of four members, ErbB1 (epidermal growth factor receptor-1), ErbB2, ErbB3, and ErbB4, which all have been found to play important roles in tumor development. ErbB4 appears to be unique among these receptors, because it is the only member with growth inhibiting properties. ErbB4 plays well-defined roles in normal tissue development, in particular the heart, the nervous system, and the mammary gland system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-020-00499-4DOI Listing

Intraductal carcinoma of the prostate.

Pathologica 2020 Mar;112(1):17-24

Vanderbilt University Medical Center, Nashville, USA.

Intraductal carcinoma of the prostate (IDC-P) is a diagnostic entity characterized by architecturally or cytologically malignant-appearing prostatic glandular epithelium confined to prostatic ducts. Despite its apparent nature, this lesion is associated with aggressive prostatic adenocarcinoma and is a predictor for poor prognosis when identified on biopsy or radical prostatectomy. This review discusses diagnosis, clinical features, histogenesis, and management of IDC-P, as well as current research and controversies surrounding this entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.32074/1591-951X-5-20DOI Listing

Cells of Origin for Prostate Cancer.

Authors:
Li Xin

Adv Exp Med Biol 2019 ;1210:67-86

Department of Urology, University of Washington, Seattle, WA, USA.

Comprehensive knowledge of the normal prostate epithelial lineage hierarchy is a prerequisite to investigate the identity of the cells of origin for prostate cancer. The basal and luminal cells constitute most of the prostate epithelium and have been the major focuses of the study on the cells of origin for prostate cancer. Much progress has been made during the past few decades, mainly using mouse models, to understand the inter-lineage relationship and intra-lineage heterogeneity in adults as well as the lineage plasticity during conditions of stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-32656-2_4DOI Listing
February 2020

The ongoing dilemma in pelvic lymph node dissection during radical prostatectomy: who should decide and in which patients?

J Robot Surg 2020 Jan 1. Epub 2020 Jan 1.

Advent Health Global Robotics Institute, 410 Celebration Place Suite#200, Celebration, 34747, FL, USA.

Pelvic lymph node dissection (pLND) is considered the most reliable method for the detection of lymph node metastases in prostate cancer. Current clinical guidelines recommend performing pLND in intermediate- and high-risk patients that are defined using different clinical nomograms and different cut-off values. Although the detection of lymph node metastatic disease can identify patients who could benefit from adjuvant therapies and potentially improve prostate cancer-related survival outcomes, so far there has been no level 1 evidence to support this survival benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11701-019-01041-xDOI Listing
January 2020

Interventional therapy in malignant conditions of the prostate.

Radiologe 2019 Dec;59(Suppl 1):28-39

Klinik für Strahlentherapie, MediClin Robert Janker Klinik, Bonn, Germany.

Interventional therapies are emerging modalities for the treatment of localized prostate cancer. Their aim is to reduce the morbidity associated with radical therapies (rT) by minimizing damage to non-cancerous tissue, with priority given to sparing key structures such as the neurovascular bundles, external sphincter, bladder neck, and rectum, while maintaining local cancer control. Interventional ablative technologies deliver energy in different ways to destroy cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00117-019-00632-xDOI Listing
December 2019
5 Reads

Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients.

Rev Urol 2019 ;21(2-3):85-92

Department of Urology, NYU Langone Health New York, NY.

The number of solid organ transplantations is increasing worldwide. Major medical advances have allowed for incremented survival in this population, which, because approximately 50% of recipients are over age 50 years, makes for an increasingly older population of transplant survivors. This article discusses controversies and current guidelines related to prostate cancer (PCa) screening, detection, and treatment for men in the general population. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864909PMC
January 2019

Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Nat Rev Cancer 2019 12 30;19(12):716-732. Epub 2019 Oct 30.

Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Queensland, Australia.

Experimental evidence accumulated over decades has implicated epithelial-mesenchymal plasticity (EMP), which collectively encompasses epithelial-mesenchymal transition and the reverse process of mesenchymal-epithelial transition, in tumour metastasis, cancer stem cell generation and maintenance, and therapeutic resistance. However, the dynamic nature of EMP processes, the apparent need to reverse mesenchymal changes for the development of macrometastases and the likelihood that only minor cancer cell subpopulations exhibit EMP at any one time have made such evidence difficult to accrue in the clinical setting. In this Perspectives article, we outline the existing preclinical and clinical evidence for EMP and reflect on recent controversies, including the failure of initial lineage-tracing experiments to confirm a major role for EMP in dissemination, and discuss accumulating data suggesting that epithelial features and/or a hybrid epithelial-mesenchymal phenotype are important in metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41568-019-0213-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055151PMC
December 2019
1 Read

High bisphenol A concentrations augment the invasiveness of tumor cells through Snail-1/Cx43/ERRγ-dependent epithelial-mesenchymal transition.

Toxicol In Vitro 2020 Feb 17;62:104676. Epub 2019 Oct 17.

Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland. Electronic address:

Bisphenol A (BPA) is commonly present in plastics used for food storage and preservation. The release of BPA from these products results in a permanent human exposition to BPA; however, the quality and quantity of BPA adverse effects remain a matter of controversy. The common presence of BPA in the human environment and the controversies concerning the relations of human exposition to BPA and cancer incidence justify the research on the interactions between BPA and pro-metastatic signaling in cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tiv.2019.104676DOI Listing
February 2020
1 Read

Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol.

Medicine (Baltimore) 2019 Oct;98(40):e17451

CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche.

Introduction: Prostate-specific antigen (PSA) is the main tool for early detection, risk stratification and monitoring of prostate cancer (PCa). However, there are controversies about the use of PSA as a population screening test because of the high potential for overdiagnosis and overtreatment associated. The net benefit of screening is unclear and according to the available recommendations, it should be offered to well-informed men with an adequate health status and a life-expectancy of at least 10 years or to men at elevated risk of having PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783167PMC
October 2019
1 Read

Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer.

Medicine (Baltimore) 2019 Sep;98(39):e17197

Department of Urology, Xijing Hospital, the Air Force Medical University, Xi'an.

Controversies exist between the previous two prognostic nomograms for patients with bone metastatic prostate cancer (PCa), and a nomogram applied to western patients has yet to be established. Thus, we aimed to build a reliable and generic nomogram to individualize prognosis.The independent prognostic factors were identified in a retrospective study of 1556 patients with bone metastatic PCa registered in the Surveillance, Epidemiology and End Results (SEER) database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775397PMC
September 2019
1 Read

Prostate biopsy evolution and the need for repeat biopsy - The role of image and new prostate cancer biomarkers.

Arch Esp Urol 2019 Sep;72(7):677-689

Department of Urology. Hospital de Santo António. C.H.P. Porto. Portugal.

Prostate Cancer (PC) is the most common malignancy in men, and a diagnosis can only be confirmed following a prostate biopsy (PB). 10-12 cores ultrasound-guided PB is currently the state of the art in the primary diagnosis of PC, presenting clear advantages in terms of detection rate of clinically significant PC, pathology concordance, and both positive and negative predictive value, when compared with the former classical sextant biopsy. Persistent clinical suspicion of PC despite previous negative PB is a challenging topic, with several serum and urinary markers, as well as imaging techniques, aiming to help in the optimal management of these patients. Read More

View Article

Download full-text PDF

Source
September 2019

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.

Int J Urol 2019 Oct 10;26(10):956-970. Epub 2019 Jun 10.

Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Gunma, Japan.

Differences in the incidence and mortality rate of prostate cancer between the USA and Japan have been decreasing over time, and were only twofold in 2017. Therefore, countermeasures against prostate cancer could be very important not only in Western countries, but also in developed Asian countries. Screening for prostate cancer in the general population using transrectal ultrasonography, digital rectal examination and/or prostate acid phosphatase began in Japan in the early 1980s, and screening with prostate-specific antigen and digital rectal examination has been widespread in the USA since the late 1980s. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.14039DOI Listing
October 2019
21 Reads

Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.

Prostate Cancer Prostatic Dis 2019 12 9;22(4):509-521. Epub 2019 Apr 9.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Advances in radiation technology have transformed treatment options for patients with localized prostate cancer. The evolution of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) have allowed physicians to spare surrounding normal organs and reduce adverse effects. The introduction of proton beam technology and its physical advantage of depositing its energy in tissue at the end-of-range maximum may potentially spare critical organs such as the bladder and rectum in prostate cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0140-7DOI Listing
December 2019
5 Reads

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

ESMO Open 2019 12;4(Suppl 1):e000471. Epub 2019 Mar 12.

Department of Urology, Juntendo University, Tokyo, Japan.

Oligometastatic disease was proposed by Hellman and Weichselbaum in 1995 as an intermediate tumour state between localised lesions and widespread metastases, characterised by the limited number and size of metastases in specific organs such as lung, liver, bone or even brain. The oligometastatic state has increasingly been recognised as a unique clinical state during which local ablative treatment can be effective in several types of cancer, including prostate cancer. However, the role of systemic therapy, such as hormone therapy and chemotherapy, is not yet well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435248PMC
March 2019
5 Reads

TRPM2 in Cancer.

Authors:
Barbara A Miller

Cell Calcium 2019 06 6;80:8-17. Epub 2019 Mar 6.

Departments of Pediatrics, and Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033, USA. Electronic address:

The TRP ion channel TRPM2 has an essential function in cell survival and protects the viability of a number of cell types after oxidative stress. It is highly expressed in many cancers including breast, prostate, and pancreatic cancer, melanoma, leukemia, and neuroblastoma, suggesting it promotes cancer cell survival. TRPM2 is activated by production of ADP-ribose (ADPR) following oxidative stress, which binds to the C-terminus of TRPM2, resulting in channel opening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ceca.2019.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545160PMC
June 2019
2 Reads

[Current controversies in the treatment of localized prostate cancer].

Urologe A 2019 May;58(5):524-528

Urologische Klinik und Poliklinik, Klinikum der Universität München, Marchioninistraße 15, 81377, München, Deutschland.

In the prostate-specific antigen (PSA) era, most prostate cancers (PCa) are diagnosed in a localized stage and a plethora of therapeutic options are warranted in different clinical settings and disease stages of localized PCa. In the current narrative review, we give an overview of the current controversies in the therapeutic landscape of localized PCa and focus on organ-sparing approaches, percutaneous radiotherapy, brachytherapy as well as retropubic and robot-assisted prostatectomy by summarizing studies that have been published within the last two years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-019-0903-8DOI Listing
May 2019
5 Reads

Editorial comment on Evolution, controversies and the future of prostate cancer grading.

Authors:
Toyonori Tsuzuki

Pathol Int 2019 02 9;69(2):67. Epub 2019 Feb 9.

Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12773DOI Listing
February 2019
17 Reads

Evolution, controversies and the future of prostate cancer grading.

Pathol Int 2019 Feb 29;69(2):55-66. Epub 2019 Jan 29.

Aquesta Uropathology and University of Queensland, Brisbane, Queensland, Australia.

Histological grading of prostate cancer is one of the most important tissue-based parameters for prediction of outcome and treatment response. Gleason grading remains the foundation of prostate cancer grading, but has undergone a series of changes in the past 30 years, often initiated by consensus conference decisions. This review summarizes the most important modifications that were introduced by the 2005 and 2014 International Society of Urological Pathology (ISUP) revisions of Gleason grading and discusses the impact that these have had on current grading practices. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pin.12761
Publisher Site
http://dx.doi.org/10.1111/pin.12761DOI Listing
February 2019
6 Reads

Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?

World J Urol 2019 Feb 4;37(2):277-287. Epub 2019 Jan 4.

Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Purpose: To review the evidence addressing current controversies around prostate biopsy. Specific questions explored were (1) mpMRI targeted (TgBx) alone versus combined with systematic (SBx) biopsy; (2) cognitive versus software-based targeted biopsy; (3) transrectal or transperineal route (TP).

Methods: We performed a literature search of peer-reviewed English language articles using PubMed and the words "prostate" AND "biopsy". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-02622-5DOI Listing
February 2019
13 Reads

Current controversies on the role of lymphadenectomy for prostate cancer.

Urol Oncol 2019 03 19;37(3):219-226. Epub 2018 Dec 19.

The Smith Institute for Urology, Zucker School of Medicine Hofstra/Northwell, New Hyde Park, NY. Electronic address:

Lymph node dissection is part of the standard treatment protocol for various cancers, but its role in prostate cancer has been debatable for some time. Pelvic lymphadenectomy has been shown to better help stage prostate cancer patients, but has yet to be definitively proven to be of any benefit for survival. Various templates for lymph node dissections exist, and though some national guidelines have endorsed an extended pelvic node dissection, the choice of template is still controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.11.020DOI Listing
March 2019
18 Reads

Laparoscopic transperitoneal inguinal hernioplasty (TAPP) after radical open retropubic prostatectomy: special features and clinical outcomes.

Authors:
W K J Peitsch

Hernia 2019 04 7;23(2):281-286. Epub 2018 Nov 7.

Department of General, Visceral, Vascular and Trauma Surgery, St. Josef Hospital Werden, University Medicine Essen, Propsteistrasse 2, 45239, Essen, Germany.

Purpose Laparoscopic transperitoneal endoscopic (TAPP) and totally extraperitoneal (TEP) hernia repair have been well established in primary and recurrent inguinal hernias [1]. Only few studies [2-5] evaluate the surgical outcome of patients with inguinal hernias after radical prostatectomy, using the TAPP or TEP procedure. But controversies remain including its feasibility, safety and recurrence rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10029-018-1846-5DOI Listing
April 2019
19 Reads

[Prostate cancer screening: controversies and suggested solutions].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018 Dec;61(12):1544-1550

Klinik für Urologie, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Prostate cancer is the most common cancer among men in industrialized countries. The annual incidence rate in Germany is about 60,000. Every year, 13,000 men die of this disease. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00103-018-2840-x
Publisher Site
http://dx.doi.org/10.1007/s00103-018-2840-xDOI Listing
December 2018
17 Reads

Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer.

Adv Exp Med Biol 2018;1096:87-98

Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.

Purpose of this chapter To demonstrate the timing, benefits, limitations and current controversies of multiparametric magnet resonance imaging (mpMRI) combined with fusion guided biopsy and consider how additional incorporation of multivariable risk stratification might further improve prostate cancer (PC) diagnosis. Recent findings MpMRI has been shown to add important information to the diagnostic pathway for prostate cancer. Fusion biopsy has also shown advantages in comparison to standard practice for biopsy-naïve men and men with previous biopsy in large prospective studies providing level 1b evidence. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99286-0_5
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99286-0_5DOI Listing
July 2019
43 Reads

Prostate Cancer Pathology: Recent Updates and Controversies.

Authors:
Jennifer K Sehn

Mo Med 2018 Mar-Apr;115(2):151-155

Jennifer K. Sehn, MD, is Assistant Professor, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.

Prostate cancer is common, and recent efforts in clinical management have focused on identifying patients who could be candidates from less aggressive management or who could benefit from more aggressive therapy. As prostate cancer histology, especially Gleason score, plays a critical role in predicting patient outcomes, attempts have been made to refine histologic classification and reporting in prostate cancer to facilitate patient risk stratification. This review discusses recent updates in prostate cancer grading and reporting. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139855PMC
August 2019
10 Reads

Novel Diagnostic Biomarkers of Prostate Cancer: An Update.

Curr Med Chem 2019 ;26(6):1045-1058

Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy.

Objective: In recent years, several biomarkers alternative to standard prostate specific antigen (PSA) for prostate cancer (PCa) diagnosis have become available. The aim of this systematic review is to assess the current knowledge about alternative serum and urinary biomarkers for the diagnosis of PCa.

Material And Methods: A research was conducted in Medline, restricted to English language articles published between December 2014 and June 2018 with the aim to update previously published series on PCa biomarkers. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165460/article
Publisher Site
http://dx.doi.org/10.2174/0929867325666180914115416DOI Listing
June 2019
49 Reads

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.

Urol Oncol 2018 09 6;36(9):401.e1-401.e9. Epub 2018 Aug 6.

Department of Urology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.

Objectives: Magnetic resonance imaging/transrectal ultrasound (MRI/TRUS) fusion-guided focal high intensity focused ultrasound (HIFU) therapy of the prostate has recently been developed as a selective HIFU-therapy technique to enable targeted ablation of prostate cancer. Here we report a series of patients treated with focal HIFU therapy, discuss its potential pitfalls, and address controversies concerning the indications.

Materials And Methods: This single-center prospective study reports outcomes of patients treated from September 2014 to March 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.05.022DOI Listing
September 2018
26 Reads

Contemporary role of postoperative radiotherapy for prostate cancer.

Transl Androl Urol 2018 Jun;7(3):399-413

Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.

While radical prostatectomy (RP) has provided long-term disease control for the majority of patients with localized prostate cancer (CaP), nearly 30% of all surgical patients have disease progression. For high-risk patients, more than half of men experience disease recurrence within 10 years. Postoperative radiotherapy is the only known potentially curative treatment for a large number of patients following prostatectomy. Read More

View Article

Download full-text PDF

Source
http://tau.amegroups.com/article/view/19832/19870
Publisher Site
http://dx.doi.org/10.21037/tau.2018.06.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043752PMC
June 2018
35 Reads

Treatment of hormone-naïve metastatic prostate cancer.

Curr Opin Support Palliat Care 2018 09;12(3):334-338

Département De Médecine Oncologique, Institut Gustave Roussy, Université Paris-Saclay, Paris, France.

Purpose Of Review: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-naïve prostate cancer (mHNPC). In the last decade, important landmark therapeutic advances occurred in the management of these patients permitting improvement of their survival.

Recent Findings: At least two prospective randomized trials proved upfront docetaxel (DOC) + ADT benefit consequently providing strong evidence for guidelines modifications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0000000000000359DOI Listing
September 2018
6 Reads

The role of CD133 in cancer: a concise review.

Clin Transl Med 2018 Jul 9;7(1):18. Epub 2018 Jul 9.

Department of Pharmacology, University of Minnesota Medical School, Nils Hasselmo Hall 3-104, 312 Church St. SE, Minneapolis, MN, 55455, USA.

Despite the abundant ongoing research efforts, cancer remains one of the most challenging diseases to treat globally. Due to the heterogenous nature of cancer, one of the major clinical challenges in therapeutic development is the cancer's ability to develop resistance. It has been hypothesized that cancer stem cells are the cause for this resistance, and targeting them will lead to tumor regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40169-018-0198-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035906PMC
July 2018
5 Reads

Simplified Prostate Imaging Reporting and Data System for Biparametric Prostate MRI: A Proposal.

AJR Am J Roentgenol 2018 08 12;211(2):379-382. Epub 2018 Jun 12.

4 Department of Urology, Clinica Castelli, Bergamo, Italy.

Objective: We describe our institutional experience using a simplified Prostate Imaging Reporting and Data System (PI-RADS) based on biparametric prostate MRI. We discuss two important controversies: the use of gadolinium-based contrast agents and the management of PI-RADS category 3 lesions.

Conclusion: Our simplified PI-RADS identifies four categories and suggests management strategies for each. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.17.19014DOI Listing
August 2018
8 Reads

The History of Testosterone and the Evolution of its Therapeutic Potential.

Sex Med Rev 2020 Apr 13;8(2):286-296. Epub 2018 Apr 13.

Boston University School of Medicine, Boston, MA, USA.

Introduction: Testosterone therapy has been controversial since its synthesis in the 1930s to the present day. Testosterone's history provides depth and context for current controversies.

Aim: To review the history of testosterone therapy from its initial synthesis in the 1930s to the modern day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sxmr.2018.03.002DOI Listing
April 2020
4 Reads

Standards, innovations, and controversies in urologic imaging.

World J Urol 2018 05;36(5):685-686

Department of Urology, Diakonissenkrankenhaus Flensburg, University Teaching Hospital of the Christian-Albrechts-Universität Kiel, Flensburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2262-2DOI Listing
May 2018
3 Reads

Current Progress and Controversies in Prostate Cancer Management.

Chin Med J (Engl) 2017 Dec;130(24):2991-2995

Department of Urology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing 100730, China.

Objective: The optimal management strategy for prostate cancer (PCa) remains controversial. We performed a systemic review of current progress and controversies regarding the diagnosis and treatment of PCa.

Data Sources: We searched PubMed for recently published articles up to July 2017 using the following key words: "prostate cancer," "progress," "controversy," "immunotherapy," and "prevention. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00029330-201712200-0001
Publisher Site
http://dx.doi.org/10.4103/0366-6999.220317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742927PMC
December 2017
12 Reads

Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer.

Front Oncol 2017 23;7:275. Epub 2017 Nov 23.

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703698PMC
November 2017
4 Reads

Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.

PLoS One 2017 28;12(11):e0188258. Epub 2017 Nov 28.

Sydney School of Public Health, The University of Sydney, Sydney, Australia.

Background: Prostate cancer is the most commonly diagnosed non-skin cancer in men. Screening for prostate cancer is widely accepted; however concerns regarding the harms outweighing the benefits of screening exist. Although patient's play a pivotal role in the decision making process, men may not be aware of the controversies regarding prostate cancer screening. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188258PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705146PMC
December 2017
13 Reads

Radical Prostatectomy for Patients With Oligometastatic Prostate Cancer.

Oncology (Williston Park) 2017 11;31(11):794-802

Cancer progresses in a stepwise fashion. Oligometastatic cancer is an intermediate stage of tumor spread between localized disease and disseminated metastases. Oligometastatic prostate cancer is defined as up to five extrapelvic lesions on conventional imaging. Read More

View Article

Download full-text PDF

Source
November 2017
6 Reads

Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis.

Oncotarget 2017 Oct 27;8(47):83261-83269. Epub 2017 Jun 27.

MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom.

Recent studies suggested that the tumour associated macrophages may be associated with prostate cancer outcome. A meta-analysis was performed to evaluate the prognostic value of tumor associated macrophages and macrophage scavenger receptor 1, marker for a subset of macrophages, by pooled hazard ratio and 95% confidence intervals from qualified studies following a systemic search. The results indicate that higher infiltration of tumor associated macrophages predicts poor overall survival (HR=1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669966PMC
October 2017
21 Reads

Controversies in PSA screening.

Authors:
Jack O'Sullivan

Evid Based Med 2017 12 9;22(6):198. Epub 2017 Nov 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ebmed-2017-110858DOI Listing
December 2017
7 Reads

Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.

Curr Opin Urol 2018 Jan;28(1):42-45

CHRISTUS Santa Rosa Medical Center Hospital, CHRISTUS Research Institute, San Antonio, Texas, USA.

Purpose Of Review: We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use.

Recent Findings: Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention.

Summary: The main theme of the review identifies the success of reducing insignificant prostate cancer and the controversy with the increased association of higher risk prostate cancer by approximately 20%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000464DOI Listing
January 2018
6 Reads

Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer.

Curr Opin Urol 2018 03;28(2):172-177

Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.

Purpose Of Review: To discuss the timing, benefits, limitations and current controversies of multiparametric magnet resonance imaging (mpMRI) combined with fusion-guided biopsy and consider how additional incorporation of multivariable risk stratification might further improve prostate cancer diagnosis.

Recent Findings: MpMRI has been proven advantageous over standard practice for biopsy-naïve men and men with previous biopsy in large prospective studies providing level 1b evidence. Upfront multivariable risk stratification followed by or combined with mpMRI further improves diagnostic accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000461DOI Listing
March 2018
39 Reads

Concomitant bladder cancer and prostate cancer: challenges and controversies.

Nat Rev Urol 2017 Oct 16;14(10):620-629. Epub 2017 Aug 16.

Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region (Ancona), School of Medicine, United Hospitals, Via Conca 71, 60126 Torrette, Ancona, Italy.

Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2017.124DOI Listing
October 2017
9 Reads

Angiomotin Family Members: Oncogenes or Tumor Suppressors?

Int J Biol Sci 2017 1;13(6):772-781. Epub 2017 Jun 1.

Department of Oncology, the First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi Province ,710061, P.R. China.

Angiomotin (Amot) family contains three members: Amot (p80 and p130 isoforms), Amot-like protein 1 (Amotl1), and Amot-like protein 2 (Amotl2). Amot proteins play an important role in tube formation and migration of endothelial cells and the regulation of tight junctions, polarity, and epithelial-mesenchymal transition in epithelial cells. Moreover, these proteins regulate the proliferation and migration of cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijbs.19603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485632PMC
April 2018
14 Reads

Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy.

Authors:
Alvaro Morales

Can Urol Assoc J 2017 Jun;11(6):210-211

Department of Urology, Queen's University, Kingston, ON, Canada.

The paper by Shayegan et al in this issue of represents an important initial step in establishing recommendations for hormonal monitoring in men with prostate cancer on androgen-deprivation therapy (ADT). As with most subjects related to the actions of testosterone, the survey adds to the controversies, but also opens the opportunity to explore several of the concerns relevant to the hormonal management of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.4652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472468PMC
June 2017
12 Reads

Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?

Front Oncol 2017 31;7:108. Epub 2017 May 31.

Department of Radiotherapy, Centre Léon Bérard, Lyon, France.

For pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449739PMC
May 2017
20 Reads

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Curr Urol Rep 2017 Jul;18(7):50

Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA.

Purpose Of Review: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11934-017-0698-3DOI Listing
July 2017
19 Reads

Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.

Authors:
S Oudard F Courbon

Ann Oncol 2017 02;28(2):421-426

Department of Medical Imaging, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers. The purpose of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs (abiraterone acetate, enzalutamide, cabazitaxel, radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The comparison was done among three European countries (UK, Germany and France) and Canada, according to the statement of each country and to the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/annonc/article-lookup/doi/10.1093/a
Publisher Site
http://dx.doi.org/10.1093/annonc/mdw546DOI Listing
February 2017
5 Reads

[Finasteride adverse effects: An update].

Rev Med Chil 2016 Dec;144(12):1584-1590

Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872016001200010DOI Listing
December 2016
9 Reads